Business
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming investor and scientific conferences. Event:H.C. Wainwright 26th Annual Global Investment Conference (New York, NY)Presentation:September 9, 2024 at 2:00 p.m. ETFormat:Company presentation and one-on-one meetings Event:6th Annual Exosome-Based Therapeutic Summit (Boston, MA)Presentation:September 17-19, 2024Format:Company presentation and industry panel Event:2024 Cantor Fitzgerald’s Global Healthcare Conference (New York, NY)Presentation:September 18, 2024 at 8:35 a.m. ETFormat:Fireside chat and one-on-one meetings Capricor management will present updates on Capricor’s recent progress on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as other general scientific and corporate updates. For more information on these presentations, please visit Capricor's website at http://capricor.com/news/events/. About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitte...